Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple nerve block ease debilitating Post-Stroke pain?

NCT ID NCT06446960

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether numbing a nerve in the arm or leg can reduce the severe, hard-to-treat pain some people feel after a stroke. Researchers will give 36 adults either one of two numbing medicines or a saltwater injection, then measure pain changes. The goal is to see if blocking signals from the body's nerves can help when standard painkillers fail.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18 years and over with no maximum age (blocks are generally very well tolerated in the very elderly) 2. Pain in the upper or lower limb distal enough to be completely covered by a peripheral nerve block 3. Chronic pain for at least 6 months 4. Ischaemic or haemorrhagic stroke for at least 6 months documented clinically and by appropriate imaging (MRI) 5. Post-stroke central neuropathic pain defined as pain occurring in the aftermath of stroke meeting the criteria for probable or defined neuropathic pain according to the NeuPSIG algorithm and with a DN4 screening questionnaire score of at least 4 out of 10. 6. Spontaneous pain intensity greater than or equal to 4 out of 10 on an 11-point numerical scale (EN) at inclusion and randomisation (i.e. just before each block) 7. Patients affiliated to a social security scheme or beneficiaries of such a scheme 8. Stable oral analgesic pharmacological treatment for at least 2 weeks prior to inclusion 9. Acceptance and signing of the informed consent Exclusion Criteria: 1. Inability or unwillingness to sign an informed consent 2. Person subject to a legal protection measure (safeguard of justice, curatorship, guardianship) 3. Patients with ongoing psychiatric pathology (major depression, psychosis) or cognitive disorders that prevent a good understanding of the protocol and questionnaires 4. Pain that is too widespread in one hemicycle or limb and cannot be adequately covered by blocks 5. Ongoing drug or substance abuse 6. Language (aphasia) or comprehension disorders, illiteracy 7. Moderate to severe renal or hepatic impairment 8. Contraindication to local anaesthetics for use in perineural blocks (infection or acute inflammation in the injection area, known allergy). 9. Pregnancy or breastfeeding 10. Known hypersensitivity to lidocaine, levobupivacaine, amide-linked local anaesthetics or to any of the excipients contained in the specialities used in the study. 11. Patients with recurrent porphyria or severe hypotension contraindicating treatment with lidocaine and/or levobupivacaine 12. Current treatment with antiarrhythmic drugs causing torsades de pointes (amiodarone, disopyramide, quinidinics, sotalol...) or with antiarrhythmic drugs with local anaesthetic activity (mexiletine or class III antiarrhythmic drugs) and cannot be discontinued. 13. Too little pain at the time of the blocks (\< 4 out of 10) 14. Need to modify analgesic pharmacological treatment at the beginning or during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ischemic Stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Ambroise Paré

    RECRUITING

    Boulogne-Billancourt, 92100, France

  • Hôpital Raymond Poincaré

    RECRUITING

    Garches, 92380, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.